Skip to main content
FIXX logo

Leverage Shares 2X Long FIX Daily ETF (FIXX) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$4.38 -$0.6903 (-13.61%) |CouncilBullish Lean · 58 · B
P/E Ratio: 4.90| Vol: 9.1K|

P/E 4.90 means the share price is 4.90 times one year of earnings per share.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Leverage Shares 2X Long FIX Daily ETF (FIXX) trades at $4.38. Homology Medicines, Inc. is a genetic medicines company focused on developing treatments for rare genetic diseases. Sector: Healthcare.

Price as of · Last analyzed: May 9, 2026
Homology Medicines, Inc. is a genetic medicines company focused on developing treatments for rare genetic diseases. Their proprietary AAVHSc platform delivers genetic medicines in vivo through gene therapy or nuclease-free gene editing.

Analyst Coverage for FIXX: FIXX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

Council Score · Weighted Average of 3 Disciplines
Bullish Lean 58/100 · B

FIXX: 1/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Englander-style lens (simulated)Izzy Englander
Neutral read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Favorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Undervalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Leverage Shares 2X Long FIX Daily ETF (FIXX) Healthcare & Pipeline Overview

CEOPaul Alloway
Employees7
HeadquartersBedford, MA, US
IPO Year2018

Homology Medicines, Inc. pioneers genetic medicines for rare diseases, leveraging its AAVHSc platform for in vivo gene therapy and editing. With a focus on single-injection treatments targeting various tissues, the company advances clinical programs like HMI-102 for PKU, positioning itself in the competitive biotechnology landscape.

Data Provenance | Financial Data Quantitative Analysis Analysis: May 9, 2026

What Is the Investment Thesis for FIXX?

AI-written as of May 9, 2026 — figures and tone reflect the data available then, not today's score.

Homology Medicines presents a focused investment opportunity within the genetic medicine space, specifically targeting rare genetic diseases. The company's proprietary AAVHSc platform offers a differentiated approach to in vivo gene therapy and editing. The ongoing Phase 2 clinical trial for HMI-102 in adults with PKU represents a near-term catalyst. Successful clinical trial outcomes and subsequent regulatory approvals could drive significant value. The company's pipeline, including HMI-103, HMI-202, HMI-203, and HMI-104, provides additional growth potential. However, the company faces risks associated with clinical trial success, regulatory hurdles, and competition from other gene therapy companies. The current market capitalization of $0.00B may reflect investor concerns about these risks, but also presents an opportunity for significant upside if the company achieves its clinical and regulatory milestones.

Based on FMP financials and quantitative analysis

FIXX Key Highlights

AI-written as of May 9, 2026 — figures and tone reflect the data available then, not today's score.

Gross Margin of 99.5% indicates efficient cost management in research and development activities.

  • Profit Margin of 61.9% suggests effective monetization of existing assets and intellectual property.
  • Phase 2 clinical trial of HMI-102 for PKU in adults represents a key milestone with potential for significant value creation.
  • AAVHSc platform offers a differentiated approach to in vivo gene therapy and editing, potentially leading to more effective treatments.
  • Market Cap of $0.00B may indicate undervaluation relative to pipeline potential, but also reflects risks associated with clinical trials and regulatory approvals.

Who Are FIXX's Competitors?

FIXX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
BLUE bluebird bio, Inc. $4.97 0.00% $48.7M —
SRPT Sarepta Therapeutics $13.33 -5.93% $1.43B 31 5-pillar
RLYB Rallybio Corporation $15.47 -0.32% $86.6M 82 5-pillar
ICCC ImmuCell Corporation $10.92 -2.41% $99.3M 82 5-pillar
ALPX Alopexx, Inc. $10.02 +0.20% $148M 61 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.69 -5.14% $160M 72 5-pillar
CGEN Compugen Ltd. $1.84 -2.13% $174M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $2.90 -5.23% $245M 90 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FIXX's Key Strengths?

Proprietary AAVHSc platform

  • Focus on rare genetic diseases
  • Strong intellectual property portfolio
  • Experienced management team

What Are FIXX's Weaknesses?

Limited financial resources

  • Dependence on clinical trial success
  • Small number of employees
  • Early stage of development

What Could Drive FIXX Stock Higher?

Phase 2 pheNIX clinical trial results for HMI-102 in adults with PKU.

  • Potential regulatory submissions for HMI-102 following successful clinical trial results.
  • Continued advancement of HMI-103, HMI-202, HMI-203, and HMI-104 through preclinical and clinical development.

What Are the Key Risks for FIXX?

Clinical trial failures for HMI-102 or other pipeline programs.

  • Regulatory delays or rejections for its gene therapies.
  • Competition from other gene therapy companies.
  • Product liability claims related to its gene therapies.
  • Dependence on raising additional capital to fund its operations.

What Are the Growth Opportunities for FIXX?

  • Expansion into new therapeutic areas: Homology Medicines can leverage its AAVHSc platform to develop treatments for additional rare genetic diseases beyond its current pipeline. The market for rare disease therapies is substantial, with increasing regulatory support and pricing flexibility. Identifying and validating new targets for its platform could significantly expand the company's addressable market. This expansion could take 3-5 years, requiring significant investment in research and development.
  • Partnerships and collaborations: Collaborating with larger pharmaceutical companies or academic institutions could provide Homology Medicines with access to additional resources, expertise, and funding. Strategic partnerships could accelerate the development and commercialization of its pipeline products. This could involve licensing agreements, joint ventures, or co-development arrangements. Such partnerships could materialize within the next 1-2 years.
  • Geographic expansion: Homology Medicines can expand its geographic reach by seeking regulatory approvals and commercializing its products in new markets, such as Europe and Asia. The global market for gene therapies is growing rapidly, and expanding into new regions could significantly increase the company's revenue potential. This expansion would likely occur within 3-5 years after initial product approvals.
  • Advancement of pipeline programs: The successful advancement of its pipeline programs, including HMI-103, HMI-202, HMI-203, and HMI-104, represents a significant growth opportunity for Homology Medicines. Positive clinical trial results and regulatory approvals for these programs could drive substantial value creation. The timelines for these programs vary, with some potentially reaching the market within the next 3-5 years.
  • Improved AAVHSc platform: Continued refinement and improvement of the AAVHSc platform could enhance its safety, efficacy, and targeting capabilities. This could lead to the development of more effective gene therapies with broader applications. Investing in research and development to optimize the platform is crucial for maintaining a competitive advantage. This is an ongoing process with continuous improvements expected over time.

What Are FIXX's Competitive Advantages?

  • Proprietary AAVHSc platform: Homology Medicines' AAVHSc platform provides a differentiated approach to in vivo gene therapy and editing.
  • Intellectual property: The company has a strong intellectual property portfolio protecting its AAVHSc platform and gene therapy candidates.
  • Expertise in gene therapy: Homology Medicines has a team of experienced scientists and clinicians with expertise in gene therapy development.

What Does FIXX Do?

Homology Medicines, Inc., founded in 2015 and headquartered in Bedford, Massachusetts, is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases. The company's core innovation lies in its proprietary adeno-associated virus vector (AAVHSc) platform. This platform enables the delivery of genetic medicines in vivo, utilizing both gene therapy and nuclease-free gene editing techniques. Homology Medicines' AAVHSc vectors are designed to target a range of disease-relevant tissues through a single injection, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. The company's lead product candidate is HMI-102, a gene therapy currently in Phase 2 pheNIX clinical trial for the treatment of phenylketonuria (PKU) in adults. In addition to HMI-102, Homology Medicines is developing HMI-103 for the treatment of PKU in pediatric patients, HMI-202 for metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 for paroxysmal nocturnal hemoglobinuria. Homology Medicines aims to address the unmet needs of patients with rare genetic diseases through its innovative gene therapy and gene editing approaches.

What Products and Services Does FIXX Offer?

  • Develops gene therapies for rare genetic diseases.
  • Utilizes its proprietary AAVHSc platform for in vivo gene delivery.
  • Focuses on both gene therapy and nuclease-free gene editing.
  • Targets a range of disease-relevant tissues through single injections.
  • Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
  • Seeks regulatory approvals for its gene therapies.
  • Commercializes its approved gene therapies.

How Does FIXX Make Money?

  • Develops and patents novel gene therapies.
  • Conducts research and development to advance its pipeline programs.
  • Out-licenses or partners with other companies for commercialization.
  • Generates revenue through product sales and licensing agreements.

What Industry Does FIXX Operate In?

Homology Medicines operates within the rapidly evolving biotechnology industry, specifically in the genetic medicine and gene therapy segment. The market for gene therapies is projected to experience substantial growth, driven by advancements in vector technology and increasing regulatory approvals. Competition is intense, with companies like Bluebird Bio and Sarepta Therapeutics also developing gene therapies for rare diseases. Homology Medicines differentiates itself through its AAVHSc platform, which aims to improve the safety and efficacy of gene delivery.

Who Are FIXX's Key Customers?

  • Patients suffering from rare genetic diseases.
  • Healthcare providers who treat patients with rare genetic diseases.
  • Pharmaceutical companies that partner with Homology Medicines for commercialization.
Model self-rating on this text: 71% (not a measure of the evidence) Updated: May 9, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
FY2026 est

Forward Outlook

Wall Street analysts project Leverage Shares 2X Long FIX Daily ETF revenue of about $2.0M for fiscal 2026, with EPS near $-0.94.

FIXX Financials

Bull Case vs Bear Case

Bull Case

  • Proprietary AAVHSc platform
  • Focus on rare genetic diseases
  • Strong intellectual property portfolio
  • Experienced management team

Bear Case

  • Limited financial resources
  • Dependence on clinical trial success
  • Small number of employees
  • Early stage of development

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · May 2026

FIXX Latest News

No recent news available for FIXX.

FIXX Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FIXX.

Price Targets

Wall Street price target analysis for FIXX.

FIXX MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FIXX; grades run from A+ (80-100) to F (below 30).

Leadership: Paul Alloway

Unknown

Therefore, I cannot provide details about his career history, education, or previous roles.

Track Record: Information about Paul Alloway's track record is not available in the provided data. Therefore, I cannot provide details about his key achievements, strategic decisions, or company milestones under his leadership.

What Investors Ask About Leverage Shares 2X Long FIX Daily ETF (FIXX) — Healthcare

Is FIXX a good stock to buy?

Stock Expert AI does not rate FIXX buy, sell or hold. Leverage Shares 2X Long FIX Daily ETF has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the FIXX stock price today?

The last price recorded on this page for Leverage Shares 2X Long FIX Daily ETF (FIXX) is $4.38, as of the Nov 20, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for FIXX?

The main risks for Homology Medicines, Inc. include the inherent uncertainties of clinical trial outcomes, particularly for HMI-102 and other pipeline programs.

What are the key factors to evaluate for FIXX?

Evaluate FIXX on fundamentals, analyst consensus, and risk factors. P/E: 4.90x. The ongoing Phase 2 clinical trial for HMI-102 in adults with PKU represents a near-term catalyst. Not financial advice.

How frequently does FIXX data refresh on this page?

FIXX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven FIXX's recent stock price performance?

Leverage Shares 2X Long FIX Daily ETF (FIXX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AAVHSc platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider FIXX overvalued or undervalued right now?

Leverage Shares 2X Long FIX Daily ETF (FIXX) trades at 4.90x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research FIXX before investing?

Before investing in Leverage Shares 2X Long FIX Daily ETF (FIXX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SRPT · Sarepta Therapeutics · 31 /100
  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100

See all scored stocks →

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on provided data and may be limited.
  • Market data may not be real-time.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives